trending Market Intelligence /marketintelligence/en/news-insights/trending/gZ58bkvgpBxH_QpLLU5_zA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA grants Lupin tentative approval to market generic ulcer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA grants Lupin tentative approval to market generic ulcer drug

The U.S. FDA granted Lupin Ltd. tentative approval to market its balasalazide disodium tablets, a generic version of Salix Pharmaceutical Inc.'s Giazo.

The drug is meant for the treatment of ulcerative colitis in male patients above the age of 18 years.